



Chronic lymphocytic leukemia (CLL) is characterized by excessive 
proliferation and accumulation of monoclonal B lymphocytes with 
CD5+/CD19+/CD23+ phenotype in the bone marrow, peripheral 
blood, lymph nodes, and also, in some patients with aggressive 
disease, non-lymphatic organs, resulting in a reduction in the number 
of normal immunocompetent cells [1, 2].
Specific to CLL is heterogeneity in clinical course, prognosis and 
response to the treatment. The start of treatment is determined 
individually for each patient and depends on the clinical symptoms 
of advanced or progressive disease. About one third of patients have 
mild course of CLL and long survival, without the need for treatment. 
In the remaining patients, the disease is more aggressive and 
despite therapy can lead to death even within a few years from the 
diagnosis [3].
Due to such a variable clinical course, there is a need for reliable 
prognostic factors that would allow for precise determination of 
prognosis, and thus selection of the optimal time and method of 
treatment. For many years, the most important prognostic factor 
was the clinical stage assessed according to the Rai’s or Binet’s 
classification, but their main disadvantage is the inability to select the 
patients in early clinical stages in whom the aggressive course of the 
disease might be predicted with high probability [4, 5].
Many parameters with prognostic value such as: absolute lymphocytes 
count in peripheral blood, doubling time of lymphocytosis, character 
of bone marrow infiltration by leukemic lymphocytes, concentration 
of soluble CD23 and β-2 microglobulin antigen, thymidine kinase 
and lactate dehydrogenase (LDH), expression of CD38, ZAP-70 [4], 
CD69 [6] have been described in CLL. The mutational status of a 
variable part of immunoglobulin heavy chain (IgVH) and cytogenetic 
abnormalities, particularly del17p and del11q are considered to have 
the not only prognostic but also predictive value. A considerable 
disadvantage is the high cost of laboratory assays [3, 4, 7, 8]. There 
is still a need to look for new prognostic and predictive factors that 
are simple to determine and that would allow for the choice of optimal 
therapy. The first reports indicated that such a value might have the 
serum level of free light chains (sFLCs) [9].
During physiological lymphopoiesis, sFLCs are produced by 
plasmocytes and B lymphocytes in excess of heavy chains, and 
their presence can be detected in small amounts in the serum. In a 
normal, polyclonal response to antigen, the amounts of sFLC κ and λ 
produced from sFLCs are similar. In plasma cell dyscrasias, excessive 
proliferation of one cell clone and production of monoclonal protein, 
result in overproduction of one type of sFLC and κ/λ ratio (sFLCR) 
alteration [10, 11]. sFLC evaluation is used in the diagnostics and 
treatment monitoring in patients with plasmocytoma, amyloidosis, 
monoclonal gammopathy of undetermined importance, light chain 
diseases, Waldenstrom’s macroglobulinemia [12, 13, 14].
The production of monoclonal protein was also found in patients 
with non-Hodgkin lymphomas (NHL) and CLL. However, laboratory 
methods used as a standard in plasma cell dyscrasias, such as protein 
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electrophoresis and immofixation, determination of Bence-Jones 
protein concentration in urine, here very often give negative results. 
It was the introduction of the nephelometric method of quantitative 
determination of sFLCs into the haematological diagnostics that 
allowed for assessing monoclonal protein concentration and 




Peripheral blood samples were taken from 59 patients diagnosed 
with CLL at the Department of Haematooncology and Bone 
Marrow Transplantation in Lublin in 2009-2010. CLL diagnosis was 
established according IWCLL criteria [15].
Blood samples were taken at CLL diagnosis, before the start of any 
anti-leukemic treatment. Exclusion criteria were as follows: severe 
concomitant diseases (renal failure, amyloidosis, monoclonal 
gammapathy of unknown etiology, connective tissue diseases, 
autoimmune diseases, concomitant cancer, heart failure, liver failure, 
respiratory distress, the symptoms of infection or allergic diseases 
at the time of testing, transfusions of blood products in the last year, 
taking drugs that affect the function of the immune system.
In all the patients, the prognostic factors were evaluated. Clinical 
characteristics of the study group and prognostic factors are 
presented in table I.
Patients follow-up
Patients underwent clinical follow-up to assess the relation between 
sFLC concentration at CLL diagnosis on primary endpoints such as 
time to first treatment (TFT), overall response rate (ORR) to therapy 
and overall survival (OS). Evaluation of responses to anticancer 
therapy was made based on criteria of response to the treatment 
according to the criteria of International Workshop on Chronic 
Lymphocytic Leukemia (IWCLL) [15].
Blood preparation
Peripheral blood samples were collected into tubes without 
anticoagulant, and then within 2 hours centrifuged for 10 minutes at 
1600 x g at room temperature (Eppendorf 5810R, Germany). The 
prepared sera were stored at –80 ° C until further analysis.
Assessment of sFLC concentration
The sFLC were measured using a latex-enhanced immunoassay 
(Freelite; The Binding Site, Birmingham, UK) on a Cobas Integra 400 
plus analyzer (Roche Diagnostics, Mannheim, Germany). Normal 
ranges were 3.3-19.4 mg/l for κ sFLC, 5.7-26.3 mg/l for λ sFLC 
and 0.26-1.65 for κ/λ ratio (sFLCR). The analysis was performed 
according to the manufacturer’s instructions. To further dissect the 
potential predictive value of sFLC, the κ and λ FLC concentrations 
were summed to produce a new variable, summed κ and λ. Based on 
literature data [11] the cut-off point was set at 66.6 mg/l.
Table I. Clinical and laboratory characteristics of the study group
Age Md (years) ± SD (min.-max.) 64.4 ± 9.5 (44–85)
Sex female 31
man 28
Clinical stage according to the Rai classification early (0-I) 37
advanced (II-IV ) 22
CD38 (cut-off point 30%) positive 16
negative 43
ZAP-70 (cut-off point 20%) positive 18
negative 41
Cytogenetic aberrations del17p 9/25
del11q 11/25
WBC (G/l) M ± SD (min.-max.) 29.4 ± 20.1 (6.5–133.9)
ALC (G/l) M ± SD (min.-max.) 23.6 ± 19.4 (5.1–110.7)
Hgb (g/dl) M ± SD (min.-max.) 13.2 ± 1.3 (9.0–15.4)
PLT (G/l) M ± SD (min.-max.) 191.0 ± 60.0 (58.0–395.0)
β-2 microglobulin (mg/l) M ± SD (min.-max.) 3.7 ± 2.8 (1.1–17.0)
LDH (U/l) M ± SD (min.-max.) 402.5 ± 123.5 (272.0–897.0)
CD 69 M ± SD (min.-max.) 25.3 ± 18.8 (1.1–75.9)




This study was approved by the Ethics Committee of the Medical 
University of Lublin. Written informed consent was obtained from all 
patients.
Statistical analysis
The obtained results were subjected to statistical analysis based on 
Statistica 12.0 computer software (StatSoft, USA). The Shapiro-Wilk 
test was used to assess the variables. Due to the fact that no features 
of the normal distribution were found, further statistical analyzes were 
conducted on the basis of non-parametric tests. Non-parametric tests 
were used in statistical analyzes: Mann-Whitney U test (for 2-category 
variables), Kruskall-Wallis test (for more than 2-category variables), 
Spearman’s rank correlation test for studying dependencies between 
variables, and analysis Kaplan-Meier experience. In all analyzes, the 
significance level p < 0.05 was assumed as critical.
Results
sFLC and sFCLR values
The mean sFLC κ concentration in the study group was 48.6 ± 
69.5 mg/l (min. 8.4 mg/l, max. 409,5 mg/l), sFLC λ 17.5 ± 16.0 mg/l 
(min. 3.5 mg/l, max. 107.8 mg/l), summed κ and λ 66.1 ± 78.2 mg/l 
(min. 14.8 mg/l, max. 465.7 mg/l), while sFLCR 3.6 ± 4.4 (at least 
0.39, max. 24.9). Elevated sFLC κ values were found in 64.4% 
(n = 38), sFLC λ in 13.6% (n = 8), summed κ and λ in 25.4% (n = 15) 
and sFLCR in 51.8% (n = 29) patients.
Correlations between sFLC and sFLCR values and com- 
plete blood count (CBC) parameters
Statistically significant negative correlation was found between 
between sFLC λ and PLT count (p = 0.04). There was also a correlation 
between summed κ and λ WBC, ALC and Hgb concentration (table II).
Correlations between sFLC and sFCLR values and prog- 
nostic factors
sFLC κ concentration was significantly higher in patients with a 
high clinical stage of disease according to the Rai classification as 
compared to the lower stages. In addition, a positive correlation 
was found between sFLC κ concentration and β-2 microglobulin 
concentration, LDH activity and CD38 expression. For sFLC λ, 
only the correlation between their level and the β-2 microglobulin 
concentration was statistically significant. There was a correlation 
between summed κ and λ and the clinical stage of disease according 
to Rai classification, β-2 microglobulin concentration and CD38 
expression (table III and IV).
Correlations between sFLCs, sFLCR and primary end- 
points
The average follow-up time was 72.5 ± 25.2 months (min. 8 months, 
max. 129 months). 10 patients died during the follow-up.
At the time of data analysis, 49% (n = 29) patients enrolled in 
the study completed the first-line therapy. Mean TFT was 18.5 
± 24.6 months (at least 0 months, max 85 months). The following 
treatment regimens were used in the study group: chlorambucil in 
combination with prednisone (n = 12), fludarabine in combination with 
cyclophosphamide +/- rituximab (n = 9), bendamustine +/-rituximab 
Table II. Correlations between sFLC, FLCR, summated κ and λ values and complete blood count (CBC) parameters
sFLC κ (mg/dl) sFLC λ (mg/dl) summated κ and λ(mg/dl) FCLR
rho p rho p rho p rho p
WBC (G/l) 0.11 0.41 0.20 0.13 0.28 0.03 -0.07 0.59
ALC (G/l) 0.11 0.412 0.13 0.34 0.26 0.04 -0.05 0.71
Hgb (g/dl) -0.21 0.110 -0.21 0.12 -0.32 0.01 -0.02 0.85
PLT (G/l) 0.01 0.922 -0.27 0.04 -0.08 0.56 0.14 0.29
rho – Pearson’s correlation coefficient, p – probability
Table III. Correlations between sFLC, FLCR, summated κ and λ values and β-2 microglobulin values, LDH activity and CD 69 
expression
sFLC κ sFLC λ summated κ and λ FCLR
rho p rho p rho rho rho p
β-2 microglobulin 0.54 0.00002 0.37 0.005 0.69 0.0000001 0.25 0.06
LDH 0.26 0.05 -0.02 0.86 0.22 0.11 0.23 0.09
CD 69 0.08 0.52 0.19 0.14 0.18 0.17 -0.10 0.47
rho – Pearson’s correlation coefficient, p – probability
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(n = 5), CHOP/CVP (n = 3). The response to the applied treatment 
was obtained in 50% of patients. No significant relationships between 
sFLC κ and λ as well as sFLCR and ORR were found. There 
was no statistically significant correlation between the elevated 
concentrations of sFLC, sFLCR and summed κ and λ and TFT and 
OS, however, in patients with normal and elevated sFLC λ, Kaplan- 
Meier curves clearly differed (Fig. 1).
Discussion
Abnormalities in the secretion of sFLC have been previously reported 
in patients with B-cell NHL, including CLL [9]. Witzig et al. [16] analyzed 
the expression of sFLC in a population of 492 patients with newly 
diagnosed B and T-cell lymphomas. They showed that the expression 
of sFLC and abnormal sFLCR most often (79% of respondents, 
including 50% monoclonal, 29% polyclonal) were reported in 
the lymphoplasmacytic lymphoma (LPL) population, mantle cell 
lymphoma (68% of patients, 24% monoclonal; 44 % polyclonal), 
Table IV. Correlations between sFLC, FLCR, summated κ and λ values and stage of the disease according to the Rai 
classification,expression ZAP-70, CD 38 and cytogenetic risk
Stage of disease according to the Rai classification
sFLC κ ± SD (mg/dl) p sFLC λ ± SD (mg/dl) p summated κ and λ ± SD (mg/dl) p FCLR ± SD p
early 27,2 ± 26.22 0.01 14.2 ± 6.9 0.63 41.4 ± 27.4 0.005 2.2 ± 2.1 0.09
advanced 83.2 ± 100.7 23.2 ± 24.0 106.4 ± 113.5 5.1 ± 6.3
ZAP-70
sFLC κ ± SD (mg/dl) p sFLC λ ± SD (mg/dl) p summated κ and λ ± SD (mg/dl) p FCLR ± SD p
positive 57.8 ± 66.9 0.59 18.1 ± 11.0 0.31 75.9 ± 69.0 0.06 4.7 ± 6.6 0.95
negative 44.5 ± 71.0 17.2 ± 17.9 61.8 ± 82.3 2.8 ± 2.8
CD 38
sFLC κ ± SD (mg/dl) p sFLC λ ± SD (mg/dl) p summated κ and λ ± SD (mg/dl) p FCLR ± SD p
positive 91.6 ± 74.2 0.0002 16.6 ± 13.3 0.57 108.2 ± 82.4 0.001 7.3 ± 6.8 0.00001
negative 32.6 ± 61.1 17.8 ± 17.1 50.4 ± 71.4 1.9 ± 1.4
cytogenetic risk
sFLC κ ± SD (mg/dl) p sFLC λ ± SD (mg/dl) p summated κ and λ ± SD (mg/dl) p FCLR ± SD p
without del11q 
or del 17p
70.6 ± 120.8 0.80 18.9 ± 14.3 0.89 89.5 ± 141.8 0.93 2.7 ± 2.1 0.80
del11q or/and 
del 17p
50.6 ± 60.3 19.4 ± 14.5 70.0 ± 66.4 3.2 ± 4.1
SD – standard deviation, p – probability
Fig. 1. Correlation between the elevated concentrations of sFLC λ and TFT
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Burkitt/high-grade lymphoma (67% of patients, 50% monoclonal, 
27% polyclonal). The authors showed that high expression of sFLC 
(both polyclonal and monoclonal) correlated with shorter overall 
survival (OS) and time to first treatment (TFT). Interestingly enough, 
also in patients with follicular lymphoma (FL), where sFLC expression 
disorders were described least frequently (15% of respondents, 4% 
monoclonal, 11% polyclonal), significant relationship between their 
concentration and OS was noted, and in the population of patients 
with a more advanced stage of the disease (stage 3 according to 
the Ann-Arbor classification) there was a connection with EFS. They 
hypothesized that it could have been associated with co-morbidities 
and other unfavorable prognostic factors [16]. M-protein was also 
found in patients with CLL. Rochester et al. showed M-protein in the 
serum of 18 patients, indicating that sFLC assessment was superior 
to electrophoresis and immunofixation, since in 6 of 8 CLL patients, 
M-protein was only detectable by the FLC assay) [17].
There are suggestions that analysis of CLL patients with sFLC 
assays may also provide additional information regarding outcome. 
In our study, there was no significant correlation between sFLC κ 
and sFLCR concentration and parameters of the whole blood 
count, however, in the patients with elevated sFLC λ, the number 
of platelets was lower and the concentration of β-2 microglobulin 
was higher that might be associated with higher tumor burden. 
Statistical analysis confirmed also a significantly higher sFLC κ 
concentration in patients with advanced stage of disease according 
to Rai’s classification. Additionally, higher sFLC κ concentration was 
found in patients with high β-2 microglobulin concentration, high 
LDH activity and CD38-positive elevated sFLC λ. Morabito et al. 
developed a new prognostic factor – summed κ and λ. They noticed 
that this parameter is significantly higher in the sick population who 
had the required treatment. On the basis of the multivariate analysis 
performed, a relationship between the clinical evaluation and the 
cytogenetic risk, ZAP-70 expression was presented, as well [11]. The 
results of our study confirmed these observations, since summed κ 
and λ values correlated positively with WBC and ALC values, while 
negative correlation was demonstrated for Hgb concentration. The 
relationship between and the summed κ and λ values and the clinical 
stage of disease according to Rai classification, β-2 microglobulin 
concentration and CD38 expression was also established.
Attempts to find correlations between the level of sFLC expression 
and selected prognostic factors in patients with CLL were carried 
out by Pratt et al. [18] in the group of 259 patients (181 untreated 
and 78 who had received treatment). The authors identified sFLC 
concentration as one of the independent prognostic factors beside 
IgVH mutational status, β-2 microglobulin concentration and 
ZAP-70 expression. Pertiago et al. [19] also demonstrated the 
relationship between sFLC levels and the mutational status of IgVH 
and primary endpoints such as OS and TFT. Ruchlemer et al. [20] 
found a relationship between sFLCκ concentration and the clinical 
stage of the disease according to Rai’s classification as well as 
between low FLCR and worse outcome for the treatment. However, 
they did not confirm the relationship between sFLC or FLCR and 
prognostic factors such as ZAP-70 and CD38 expression, cytogenetic 
aberrations, peripheral blood leukocytosis and LDH activity [20].
On opposite, Yegin et al. [21] noted the relationship between abnormal 
sFLC and FLCR and LDH activity, hemoglobin concentration, platelet, 
leukocyte, and lymphocyte counts [21]. The relationship between 
overexpression of CD-38 antigen and increased sFLC concentration, 
might indicate that they are markers of excessive stimulation of B 
lymphocytes. The relationship between abnormal FLCR and ZAP-70, 
expression, cytogenetics aberrations, TFT in a multivariate model 
was demonstrated in a large group of 446 patients [11].
We found no differences in sFLC level between the patients with 
adverse cytogenetic aberrations (del17p and/or del11q) and/or high 
ZAP-70 expression and the population with standard cytogenetic risk 
and/or low ZAP-70 expression. However, it should be noted that this 
assessment, could be unreliable due to the small size of the group. 
Therefore, further research is needed in concerning this subject.
Our results suggest that higher sFLC κ expression in patients with 
unfavorable prognostic factors such as clinical stage according 
to Rai, β-2 microglobulin concentration, LDH activity and CD38 
expression could be helpful in selecting the population of patients 
with progressive form of the disease.
An important element in the assessment of the prognostic value of 
the studied factor is an attempt to assess its impact on the primary 
endpoints. Literature data confirmed the relationship between sFLC 
concentration and FLCR disorders and both OS and TFT. Pratt et al. 
[18] showed that high concentration of sFLC was an independent 
factor, associated with increased mortality in the studied population, 
regardless of the cause of death. Also, if only CLL-related deaths 
were taken into account, the elevated concentration of sFLC was 
associated with a shorter OS. TFT was statistically significantly longer 
in the group of patients with lower sFLC levels [18]. Also, Morabito et 
al. [11] unambiguously confirmed the relationship between abnormal 
FLC κ and λ concentration and TFT. These studies are in line with 
the results of Maurer et al. [22] who found that sFLC and FLCR can 
be considered as independent prognostic factors and translate into 
OS and TFT, regardless of whether secretion of sFLC was polyclonal 
or monoclonal. In this study, higher sFLC levels were found in older 
patients, with elevated creatinine levels that could also contribute to 
shorter OS [22].
Our own research does not confirm the relationship between sFLC, 
summed κ and λ and sFCLR and primary endpoints such as OS, 
TFT and ORR. However, it should be emphasized that CLL is an 
extremely heterogeneous disease and very often at the time of 
the diagnosis does not show clinical symptoms, and in the case of 
patients who do not perform regular check-ups, the diagnosis can 
be made even a few years after the first disturbances in peripheral 
blood morphology. The sFLC and FLCR determinations were made 
at the time of the diagnosis, therefore a meaningful determination of 
OS and TFT length in this group of patients is difficult. Also, the ORR 
assessment in such a small group of patients could not be reliable, 
especially considering the number of different treatment regimens 
that are used in everyday clinical practice and the necessity to reduce 
doses of cytostatics in older patients with numerous comorbidities. 
It would be interesting to evaluate predictive value of sFLC in larger 
group of patients treated with new agents, such as BCR or Bcl-2 
inhibitors.
Despite the fact that many prognostic factors have been identified 
so far, their role in prognosing the course of the disease and anti-
cancer therapy is very often still unclear. The introduction of new 
molecular and cytogenetic markers to everyday clinical practice is 
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very often impossible due to the high cost-effectiveness and the need 
to have adequate laboratory facilities. That is why it is important to 
look for new, cheaper markers that will allow to optimize the treatment 
choice [23]. Taking into account the results of our research and the 
literature on the subject presented above, it can be concluded that 
the evaluation of sFLC expression, summed κ and λ levels and 
sFLCR disorders in patients with CLL may be an important element 
that supplements the diagnostic procedure. It would be interesting to 
assess the predictive value of these parameters in relation to ORR, 
carried out in a larger and more homogeneous group of patients.
Authors’ contributions/ Wkład autorów
The order of the authors reflects their participation in preparation of 
the manuscript.
Conflict of interest/ Konflikt interesu 
There are no conflicts of interests. 
Financial support/ Finansowanie
This work was supported by educational grants of the Medical 
University of Lublin (DS 174/2018).
Ethics/Etyka
The work descibed in this article has been carried out in accordance 
with The Code of Ethics of the World Medical Association (Declaration 
of Helsinki) for experiments involving humans; EU Directive 2010/63/ 
EU for animal experiments; Uniform Requirements for manuscripts 
submitted to biomedical journals.
References/Piśmiennictwo
[1] Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. 
Nat Rev Dis Primers 2017;3:16096.
[2] Podhorecka M, Macheta A, Bozko M, et al. Deregulation of apoptosis 
– Is it still an important issue in pathogenesis of chronic lymphocytic 
leukemia? Curr Cancer Drug Targets 2016;16:652–8.
[3] Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, 
risk stratification, and treatment. Am J Hematol 2015;90:446–60.
[4] Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic 
factors and impact on treatment. Discov Med 2011;11:115–23.
[5] Baliakas P, Mattsson M, Stamatopoulos K, et al. Prognostic indices 
in chronic lymphocytic leukaemia: where do we stand how do we 
proceed? J Intern Med 2016;279:347–57.
[6] Grywalska E, Bartkowiak-Emeryk M, Pasiarski M, et al. Relationship 
between the expression of CD25 and CD69 on the surfance of 
lymphocytes T and B from peripherial blood and bone marrow 
of patients with chronic lymphocytic leukemia and established 
prognostic factors of this disease. Adv Clin Exp Med 2018;27:987–99.
[7] Hus I, Roliński J. Current concepts in diagnosis and treatment of 
chronic lymphocytic leukemia. Contemp Oncol (Pozn) 2015:361–7.
[8] Vyas N, Hassan A. Recent advances in chronic lymphocytic leukemia. 
Indian J Cancer 2012;49:137–43.
[9] Charafeddine KM, Jabbour MN, Kadi RH, et al. Extended use of serum 
free light chain as a biomarker in lymphoproliferative disorders: a 
comprehensive review. Am J Clin Pathol 2012;137:890–7.
[10] Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: 
clinical utility and limitations. Ann Clin Biochem 2014;51:528–42. 
[11] Morabito F, de Filippi R, Laurenti L, et al. The cumulative amount 
of serum-free light chain is a strong prognosticator in chronic 
lymphocytic leukemia. Blood 2011;118:6353–61.
[12] Dogaru M, Lazăr V, Coriu D. Assessing the efficiency of free light 
chain assay in monitoring patients with multiple myeloma before 
and after autologous stem cell transplantation along with serum 
protein electrophoresis and serum protein immunofixation. Roum 
Arch Microbiol Immunol 2011;70:15–22.
[13] Barnidge DR, Dispenzieri A, Merlini G, et al. Monitoring free light 
chains in serum using mass spectrometry. Clin Chem Lab Med 
2016;54:1073–83.
[14] Hansen CT. Performance goals for immunoglobulins and serum free 
light chain measurements in plasma cell dyscrasias can be based on 
biological variation. Clin Chem Lab Med 2016;54:1031–3.
[15] Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis 
and treatment of chronic lymphocytic leukemia: a report from the 
International Workshop on Chronic Lymphocytic Leukemia updating 
the National Cancer Institute–Working Group 1996 guidelines. Blood 
2008; 111:5446–56.
[16] Witzig TE, Maurer MJ, Habermann TM, et al. Elevated monoclonal 
and polyclonal serum immunoglobulin free light chain as prognostic 
factors in B- and T-cell non-Hodgkin lymphoma. Am J Hematol 
2014;89:1116–20.
[17] Martin W, Abraham R, Shanafelt T, et al. Serum-free light chain – 
a new biomarker for patients with B-cell non-Hodgkin lymphoma 
and chronic lymphocytic leukemia. Transl Res 2007;149:231–5.
[18] Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain 
ratios are associated with poor survival and may reflect biological 
subgroups in patients with chronic lymphocytic leukaemia. Br J 
Haematol 2009;144:217–22.
[19] Perdigao J, Cabrai MJ, Costa N, et al. Prognostic factors in CLL: is 
serum free light chain ratio a new biological marker? Annals of 
Oncology 2008;19:article 204.
[20] Ruchlemer R, Reinus C, Paz E, et al. Free light chains, monoclonal 
proteins and chronic lymphocytic leukaemia. Blood 2007;110:article 
4697a.
[21] Yegin ZA, Ozkurt ZN, Yağci M. Free light chain: a novel predictor of 
adverse outcome in chronic lymphocytic leukemia. Eur J Haematol 
2010;84:406–11.
[22] Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal 
serum free light chains and clinical outcome in chronic lymphocytic 
leukemia. Blood. 2011;118:2821–6.
[23] Fischer K, Hallek M. Optimizing frontline therapy of CLL based on 
clinical and biological factors. Hematology Am Soc Hematol Educ 
Program 2017;2017(1):338–45.
